Progress in the medicinal chemistry of silicon: C/Si exchange and beyond

Papers of special note have been highlighted as: • of interest

References

• 1 Richardson PG, Hideshima T, Anderson KC. Bortezomib (PS-341): a novel, first-in-class proteasome inhibitor for the treatment of multiple myeloma and other cancers. Cancer Control 10(5), 361–369 (2003).
  MedlineGoogle Scholar
• 2 Fu H, Fang H, Sun J et al. Boronic acid-based enzyme inhibitors: a review of recent progress. Curr. Med. Chem. 21(28), 3271–3280 (2014).
  Medline CASGoogle Scholar
• 3 Brook MA. Silicon in Organic, Organometallic, and Polymer Chemistry. John Wiley & Sons, NY, USA (2000).
  Google Scholar
• 4 Franz AK, Wilson SO. Organosilicon molecules with medicinal applications. J. Med. Chem. 56(2), 388–405 (2013).
  Medline CASGoogle Scholar
• 5 Lukevics E, Ignatovich L. Comparative study of the biological activity of organosilicon and organogermanium compounds. Appl. Organomet. Chem. 6(2), 113–126 (1992).
  CASGoogle Scholar
• 6 Mills JS, Showell GA. Exploitation of silicon medicinal chemistry in drug discovery. Expert Opin. Investig. Drugs 13(9), 1149–1157 (2004).
  Medline CASGoogle Scholar
• 7 Showell GA, Mills JS. Chemistry challenges in lead optimization: silicon isosteres in drug discovery. Drug Discov. Today 8(12), 551–556 (2003).
  Medline CASGoogle Scholar
• 8 Gately S, West R. Novel therapeutics with enhanced biological activity generated by the strategic introduction of silicon isosteres into known drug scaffolds. Drug. Dev. Res. 68(4), 156–163 (2007).
  CASGoogle Scholar
• 9 Fujii S, Miyajima Y, Masuno H, Kagechika H. Increased hydrophobicity and estrogenic activity of simple phenols with silicon and germanium-containing substituents. J. Med. Chem. 56(1), 160–166 (2013). • Systematic investigation of the physicochemical properties of various silyl and germyl functionalities.
  Medline CASGoogle Scholar
• 10 Van Hattum AH, Pinedo HM, Schlüper HMM, Hausheer FH, Boven E. New highly lipophilic camptothecin BNP1350 is an effective drug in experimental human cancer. Int. J. Cancer 88(2), 260–266 (2000).
  Medline CASGoogle Scholar
• 11 Bom D, Curran DP, Kruszewski S et al. The novel silatecan 7-tertbutyldimethylsilyl-10-hydroxycamptothecin displays high lipophilicity, improved human blood stability, and potent anticancer activity. J. Med. Chem. 43(21), 3970–3980 (2000).
  Medline CASGoogle Scholar
• 12 Daud A, Valkov N, Centeno B et al. Phase II trial of karenitecin in patients with malignant melanoma: clinical and translational study. Clin. Cancer Res. 11(8), 3009–3016 (2005).
  Medline CASGoogle Scholar
• 13 Curran DP, Du W. Palladium-promoted cascade reactions of isonitriles and 6-iodo-N-propargylpyridones: synthesis of mappicines, camptothecins, and homocamptothecins. Org. Lett. 4(19), 3215–3218 (2002).
  Medline CASGoogle Scholar
• 14 Yamakawa T, Kagechika H, Kawachi E, Hashimoto Y, Shudo K. Retinobenzoic acids. 5. Retinoidal activities of compounds having a trimethylsilyl or trimethylgermyl group(s) in human promyelocytic leukemia cells HL-60. J. Med. Chem. 33(5), 1430–1437 (1990).
  Medline CASGoogle Scholar
• 15 Higginbotham KB, Lozano R, Brown T et al. A Phase I/II trial of TAC-101, an oral synthetic retinoid, in patients with advanced hepatocellular carcinoma. J. Cancer Res. Clin. Oncol. 134(12), 1325–1335 (2008).
  Medline CASGoogle Scholar
• 16 Yamanoi Y, Nishihara H. Direct and selective arylation of tertiary silanes with rhodium catalyst. J. Org. Chem. 73(17), 6671–6678 (2008).
  Medline CASGoogle Scholar
• 17 Förster B, Bertermann R, Kraft P, Tacke R. Sila-rhubafuran and derivatives: synthesis and olfactory characterization of novel silicon-containing odorants. Organometallics 33(1), 338–346 (2014). • As recent examples of silicon-containing odorants.
  Google Scholar
• 18 Friedrich J, Dörrich S, Berkefeld, Kraft P, Tacke R. Synthesis and olfactory characterization of sila-methyl pamplemousse and related odorants with a 2,2,5-trimethyl-2-silahex-4-ene skeleton. Organometallics 33(3), 796–803 (2014).
  CASGoogle Scholar
• 19 Tacke R, Handmann VI. Derivatives of β-(trimethylsilyl)alanine with SiCH₂NH₂, SiCH₂OH, or SiCH₂SH functionality: synthesis of the silicon-containing α-amino acids rac- and (R)-Me₂Si(CH₂R)CH₂CH(NH₂)COOH (R = NH₂, OH, SH). Organometallics 21(13), 2619–2626 (2002). • As examples of silicon-containing amino acids.
  CASGoogle Scholar
• 20 Falgner S, Buchner G, Tacke R. Synthesis of rac-2′-(trimethylsilyl)isovaline: a novel silicon-containing α,α-dialkylated α-amino acid. J. Organomet. Chem. 695(24), 2614–2617 (2010).
  CASGoogle Scholar
• 21 Klapötke TM, Krumm B, Ilg R, Troegel D, Tacke R. The sila-explosives Si(CH₂N₃)₄ and Si(CH₂ONO₂)₄: silicon analogs of the common explosives pentaerythrityl tetraazide, C(CH₂N₃)₄, and pentaerythritol tetranitrate, C(CH₂ONO₂)₄. J. Am. Chem. Soc. 129(21), 6908–6915 (2007).
  MedlineGoogle Scholar
• 22 Ohnishi K. PML-RAR-α inhibitors (ATRA, tamibaroten, arsenic troxide) for acute promyelocytic leukemia. Int. J. Clin. Oncol. 12(5), 313–317 (2007).
  Medline CASGoogle Scholar
• 23 Tanaka T, De Luca LM. Therapeutic potential of “rexinoids” in cancer prevention and treatment. Cancer Res. 69(12), 4945–4947 (2009).
  Medline CASGoogle Scholar
• 24 Tacke R, Müller V, Büttner MW et al. Synthesis and pharmacological characterization of disila-AM80 (disilatamibarotene) and disila-AM580, silicon analogs of the RAR-α-selective retinoid agonists AM80 (tamibarotene) and AM580. ChemMedChem 4(11), 1797–1802 (2009).
  Medline CASGoogle Scholar
• 25 Büttner MW, Burschka C, Daiss JO et al. Silicon analogs of the retinoid agonists TTNPB and 3-methyl-TTNPB, disila-TTNPB and disila-3-methyl-TTNPB: chemistry and biology. ChemBioChem 8(14), 1688–1699 (2007). • Together with their retinoid X receptor ligands (Reference 28 in this list), suggestive discussions about Si/C-exchange based on x-ray co-crystal analyses were provided.
  Medline CASGoogle Scholar
• 26 Gluyas JBG, Burschka C, Dörrich S, Vallet J, Gronemeyer H, Tacke R. Disila-analogs of the synthetic retinoids EC23 and TTNN: synthesis, structure and biological evaluation. Org. Biomol. Chem. 10(34), 6914–6929 (2012).
  Medline CASGoogle Scholar
• 27 Daiss JO, Burschka C, Mills JS et al. Synthesis, crystal structure analysis, and pharmacological characterization of disila-bexarotene, a disila-analog of the RXR-selective retinoid agonist bexarotene. Organometallics 24(13), 3192–3199 (2005).
  CASGoogle Scholar
• 28 Lippert WP, Burschka C, Götz K et al. Silicon analogs of the RXR-selective retinoid agonist SR11237 (BMS649): chemistry and biology. ChemMedChem 4(7), 1143–1152 (2009).
  Medline CASGoogle Scholar
• 29 Bauer JB, Lippert WP, Dörrich S et al. Novel silicon-containing analogs of the retinoid agonist bexarotene: syntheses and biological effects on human pluripotent stem cells. ChemMedChem 6(8), 1509–1517 (2011).
  Medline CASGoogle Scholar
• 30 Büttner MW, Nätscher JB, Burschka C, Tacke R. Development of a new building block for the synthesis of silicon-based drugs and odorants: alternative synthesis of the retinoid agonist disila-bexarotene. Organometallics 26(19), 4835–4838 (2007).
  CASGoogle Scholar
• 31 Barnes MJ, Burschka C, Büttner MW et al. Silicon analogs of the nonpeptidic GnRH antagonist AG-045572: syntheses, crystal structure analyses, and pharmacological characterization. ChemMedChem 6(11), 2070–2080 (2011).
  Medline CASGoogle Scholar
• 32 Toyama H, Nakamura M, Nakamura M, Matsumoto Y, Nakagomi M, Hashimoto Y. Development of novel silicon-containing inverse agonists of retinoic acid receptor-related orphan receptors. Bioorg. Med. Chem. 22(6), 1948–1959 (2014).
  Medline CASGoogle Scholar
• 33 Tacke R, Handmann VI, Bertermann R, Burschka C, Penka M, Seyfried C. Sila-analogs of high-affinity, selective ó ligands of the spiro[indane-1,4′-piperidine] type: syntheses, structures, and pharmacological properties. Organometallics 22(5), 916–924 (2003).
  CASGoogle Scholar
• 34 Tacke R, Bertermann R, Burschka C et al. High-affinity, selective ó ligands of the 1,2,3,4-tetrahydro-1,4′-silaspiro[naphthalene-1,4′-piperidine] type: syntheses, structures, and pharmacological properties. ChemMedChem 7(3), 523–532 (2012).
  Medline CASGoogle Scholar
• 35 Geyer M, Baus JA, Fjellström O, Wellner E, Gustafsson L, Tacke R. Synthesis and pharmacological properties of silicon-containing GPR81 and GPR109A agonists. ChemMedChem 10(12), 2063–2070 (2015).
  Medline CASGoogle Scholar
• 36 Fischer M, Burschka C, Tacke R. Synthesis of 4-silacyclohexan-1-ones and (4-silacyclohexan-1-yl)amines containing the silicon protecting groups MOP (4-methoxyphenyl), DMOP (2,4-dimethoxyphenyl), or TMOP (2,4,6-trimethoxyphenyl): versatile Si- and C-functional building blocks for synthesis. Organometallics 33(4), 1020–1029 (2014).
  CASGoogle Scholar
• 37 Geyer M, Karlsson O, Baus JA, Wellner E, Tacke R. Si- and C-functional organosilicon building blocks for synthesis based on 4-silacyclohexan-1-ones containing the silicon protecting groups MOP (4-methoxyphenyl), DMOP (2,6-dimethoxyphenyl), or TMOP (2,4,6-trimethoxyphenyl). J. Org. Chem. 80(11), 5804–5811 (2015).
  Medline CASGoogle Scholar
• 38 Seetharamsingh B, Ramesh R, Dange SS et al. Design, synthesis, and identification of silicon incorporated oxazolidinone antibiotics with improved brain exposure. ACS Med. Chem. Lett. 6(11), 1105–1110 (2015).
  Medline CASGoogle Scholar
• 39 Jachak GR, Ramesh R, Sant DG et al. Silicon incorporated morpholine antifungals: design, synthesis, and biological evaluation. ACS Med. Chem. Lett. 6(11), 1111–1116 (2015).
  Medline CASGoogle Scholar
• 40 Boehm MF, Fitzgerald P, Zou A et al. Novel nonsecosteroidal vitamin D mimics exert VDR-modulating activities with less calcium mobilization than 1,25-dihydroxyvitamin D₃. Chem. Biol. 6(5), 265–275 (1999).
  Medline CASGoogle Scholar
• 41 Hosoda S, Tanatani A, Wakabayashi K et al. Ligands with dual vitamin D₃-agonistic and androgen-antagonistic activities. Bioorg. Med. Chem. Lett. 15(19), 4327–4331 (2005).
  Medline CASGoogle Scholar
• 42 Nakamura M, Makishima M, Hashimoto Y. Development of silicon-containing bis-phenol derivatives as androgen receptor antagonists: selectivity switching by C/Si exchange. Bioorg. Med. Chem. 21(7), 1643–1651 (2013).
  Medline CASGoogle Scholar
• 43 Kajita D, Nakamura M, Matsumoto Y, Makishima M, Hashimoto Y. Design and synthesis of silicon-containing steroid sulfatase inhibitors possessing pro-estrogen antagonistic character. Bioorg. Med. Chem. 22(7), 2244–2252 (2014).
  Medline CASGoogle Scholar
• 44 Daiss JO, Duda-Johner S, Burschka C, Holzgrabe U, Mohr K, Tacke R. N⁺/Si replacement as a tool for probing the pharmacophore of allosteric modulators of muscarinic M₂ receptors: synthesis, allosteric potency, and positive cooperativity of silicon-based W84 derivatives. Organometallics 21(5), 803–811 (2002).
  CASGoogle Scholar
• 45 Duda-Johner S, Daiß JO, Mohr K, Tacke R. Synthesis and pharmacological characterization of new silicon-based W84-type allosteric modulators for ligand binding to muscarinic M₂ receptors. J. Organomet. Chem. 686(1–2), 75–83 (2003).
  CASGoogle Scholar
• 46 Daiss JO, Albrecht M, Mohr K, Tacke R. A novel silicon-based uncharged allosteric modulator for ligand binding to muscarinic M₂ receptors: synthesis and pharmacological characterization. Organometallics 23(25), 6052–6057 (2004).
  CASGoogle Scholar
• 47 Kajita D, Nakamura M, Matsumoto Y, Ishikawa M, Hashimoto Y, Fujii S. Design and synthesis of silicon-containing fatty acid amide derivatives as novel peroxisome proliferator-activated receptor (PPAR) agonists. Bioorg. Med. Chem. Lett. 25(16), 3350–3354 (2015).
  Medline CASGoogle Scholar
• 48 Nakamura M, Kajita D, Matsumoto Y, Hashimoto Y. Design and synthesis of silicon-containing tubulin polymerization inhibitors: replacement of the ethylene moiety of combretastatin A-4 with a silicon linker. Bioorg. Med. Chem. 21(23), 7381–7391 (2013).
  Medline CASGoogle Scholar
• 49 Nishiyama Y, Nakamura M, Misawa T et al. Structure-activity relationship-guided development of retinoic acid receptor-related orphan receptor gamma (ROR-γ)-selective inverse agonists with a phenanthridin-6(5H)-one skeleton from a liver X receptor ligand. Bioorg. Med. Chem. 22(9), 2799–2808 (2014).
  Medline CASGoogle Scholar
• 50 Toyama H, Nakamura M, Hashimoto Y, Fujii S. Design and synthesis of novel ROR inverse agonists based on dibenzosilole scaffolds as a hydrophobic core structure. Bioorg. Med. Chem. 23(13), 2982–2988 (2015).
  Medline CASGoogle Scholar
• 51 Balzarini J, Pérez-Pérez M-J, San-Félix A et al. 2′,5′-Bis-O-(tert-butyldimethylsilyl)-3′-spiro-5′′-(4′′-amino-1′′,2′′-oxathiole-2′′,2′′-dioxide)pyrimidine(TSAO) nucleoside analogs: highly selective inhibitors of human immunodeficiency virus type 1 that are targeted at the viral reverse transcriptase. Proc. Natl Acad. Sci. USA 89(10), 4392–4396 (1992).
  Medline CASGoogle Scholar
• 52 Camarasa M-J, Pérez-Pérez M-J, San-Félix A, Balzarini J, De Clercq E. 3′-Spiro nucleosides, a new class of specific human immunodeficiency virus type 1 inhibitors: synthesis and antiviral activity of [2′,5′-bis-O-(tert-butyldimethylsilyl)-β-D-xylo- and-ribofuranose]-3′-spiro-5′′-[4′′-amino-1′′,2′′-oxathiole2′′,2′′-dioxide] (TSAO) pyrimidine nucleosides. J. Med. Chem. 35(15), 2721–2727 (1992).
  Medline CASGoogle Scholar
• 53 Das K, Bauman JD, Rim AS et al. Crystal structure of tert-butyldimethylsilylspiroaminooxathioledioxide-thymine (TSAO-T) in complex with HIV-1 reverse transcriptase (RT) redefines the elastic limits of the non-nucleoside inhibitor-binding pocket. J. Med. Chem. 54(8), 2727–2737 (2011).
  Medline CASGoogle Scholar
• 54 Chen H, Liu L, Jones SA et al. Selective inhibition of the West Nile virus methyltransferase by nucleoside analogs. Antiviral Res. 97(3), 232–239 (2013).
  MedlineGoogle Scholar
• 55 Vernekar SKV, Qiu L, Zhang J et al. 5-Silylated 3′-1,2,3-triazolyl thymidine analogs as inhibitors of West Nile virus and Dengue virus. J. Med. Chem. 58(9), 4016–4028 (2015).
  Medline CASGoogle Scholar
• 56 Panayides JL, Mathieu V, Banuls LMY et al. Synthesis and in vitro growth inhibitory activity of novel silyl- and trityl-modified nucleosides. Bioorg. Med. Chem. 24(12), 2716–2724 (2016).
  Medline CASGoogle Scholar
• 57 Wohl AR, Michel AR, Kalscheuer S, Macosko CW, Panyam J, Hoye TR. Silicate esters of paclitaxel and docetaxel: synthesis, hydrophobicity, hydrolytic stability, cytotoxicity, and prodrug potential. J. Med. Chem. 57(6), 2368–2379 (2014).
  Medline CASGoogle Scholar
• 58 Chandrasekhar V, Boomishankar R, Nagendran S. Recent developments in the synthesis and structure of organosilanols. Chem. Rev. 104(12), 5847–5910 (2004). • For review of organosilanols.
  Medline CASGoogle Scholar
• 59 Sieburth SMcN, Chen C-A. Silanediol protease inhibitors: from conception to validation. Eur. J. Org. Chem. 2006(2), 311–322 (2006). • For review of silanediol type transition state analogs.
  Google Scholar
• 60 Chen C-A, Sieburth SMcN, Glekas A et al. Drug design with a new transition state analog of the hydrated carbonyl: silicon-based inhibitors of the HIV protease. Chem. Biol. 8(12), 1161–1166 (2001).
  Medline CASGoogle Scholar
• 61 Sieburth SMcN, Nittoli T, Mutahi AM, Guo L. Silanediols: a new class of potent protease inhibitors. Angew. Chem. Int. Ed. Engl. 37(6), 812–814 (1998). • Excellent utilization of silanediols in the field of medicinal chemistry.
  Medline CASGoogle Scholar
• 62 Mutahi MW, Nittoli T, Guo L, Sieburth SMcN. Silicon-based metalloprotease inhibitors: synthesis and evaluation of silanol and silanediol peptide analogs as inhibitors of angiotensin-converting enzyme. J. Am. Chem. Soc. 124(25), 7363–7375 (2002).
  Medline CASGoogle Scholar
• 63 Madsen JL, Andersen TL, Santamaria S, Nagase H, Enghild JJ, Skrydstrup T. Synthesis and evaluation of silanediols as highly selective uncompetitive inhibitors of human neutrophil elastase. J. Med. Chem. 55(17), 7900–7908 (2012).
  Medline CASGoogle Scholar
• 64 Hernández D, Lindsay KB, Nielsen L et al. Further studies toward the stereocontrolled synthesis of silicon-containing peptide mimics. J. Org. Chem. 75(10), 3283–3293 (2010).
  Medline CASGoogle Scholar
• 65 Madsen AS, Kristensen HME, Lanz G, Olsen CA. The effect of various zinc binding groups on inhibition of histone deacetylases 1–11. ChemMedChem 9(3), 614–626 (2014).
  Medline CASGoogle Scholar
• 66 Steiling L, Tacke R, Wannagat U. Sila-Pharmaka, 11. Diphenyl(3-piperidinopropyl)silanol, ein Sila-Analogon des Difenidols. Liebigs Ann. Chem. 1979(10), 1554–1559 (1979).
  Google Scholar
• 67 Tacke R, Strecker M, Sheldrick WS et al. Sila-Pharmaka, XIX. Sila-Pridinol und Pridinol: Darstellung und Eigenschaften sowie Strukturen im kristallinen und gelösten Zustand. Chem. Ber. 113(5), 1962–1980 (1980).
  CASGoogle Scholar
• 68 Tacke R, Pikies J, Linoh H, Rohr-Aehle R, Gönne S. Sila-Pharmaka, 36. Sila-Procyclidin: Eine neue Synthese sowie Untersuchungen zur peripheren und zentralen anticholinergen Wirkung. Liebigs Ann. Chem. 1987(1), 51–57 (1987).
  Google Scholar
• 69 Waelbroeck M, Camus J, Tastenoy M et al. Thermodynamics of antagonist binding to rat muscarinic M₂ receptors: antimuscarinics of the pridinol, sila-pridinol, diphenidol and sila-diphenidol type. Br. J. Pharmacol. 109(2), 360–370 (1993).
  Medline CASGoogle Scholar
• 70 Lambrecht G, Feifel R, Wagner-Röder M et al. Affinity profiles of hexahydro-sila-difenidol analogs at muscarinic receptor subtypes. Eur. J. Pharmacol. 168(1), 71–80 (1989).
  Medline CASGoogle Scholar
• 71 Tacke R, Mahner K, Strohmann C et al. Cyclohexyl(4-fluorophenyl)(3-piperidinopropyl)silanol (p-fluoro-hexahydro-sila-difenidol, p-F-HHSiD) and derivatives: synthesis and antimuscarinic properties. J. Organomet. Chem. 417(3), 339–353 (1991).
  CASGoogle Scholar
• 72 Tacke R, Reichel D, Knopfgans M et al. Biological recognition of enantiomeric silanes: syntheses and antimuscarinic properties of optically active (2-aminoethyl)cyclohexyl(hydroxymethy1)phenylsilanes and related quaternary ammonium derivatives. Organometallics 14(1), 251–262 (1995).
  CASGoogle Scholar
• 73 Tacke R, Reichel D, Jones PG et al. Pharmacological discrimination between enantiomeric germanes by muscarinic receptors: a study on germanium/silicon bioisosterism. J. Organomet. Chem. 521(1–2), 305–323 (1996).
  CASGoogle Scholar
• 74 Tacke R, Kornek T, Heinrich T et al. Syntheses and pharmacological characterization of achiral and chiral enantiopure C/Si/Ge-analogous derivatives of the muscarinic antagonist cycrimine: a study on C/Si/Ge bioisosterism. J. Organomet. Chem. 640(1–2), 140–165 (2001).
  CASGoogle Scholar
• 75 Tacke R, Schmid T, Penka M, Burschka C, Bains W, Warneck J. Syntheses and pharmacological properties of the histaminic H₁ antagonists sila-terfenadine-A, sila-terfenadine-B, disila-terfenadine, and sila-fexofenadine: a study on C/Si bioisosterism. Organometallics 23(21), 4915–4923 (2004).
  CASGoogle Scholar
• 76 Daiss JO, Burschka C, Mills JS et al. Sila-venlafaxine, a sila-analog of the serotonin/noradrenaline reuptake inhibitor venlafaxine: synthesis, crystal structure analysis, and pharmacological characterization. Organometallics 25(5), 1188–1198 (2006).
  CASGoogle Scholar
• 77 Tacke R, Heinrich T, Bertermann R, Burschka C, Hamacher A, Kassack MU. Sila-haloperidol: a silicon analog of the dopamine (D₂) receptor antagonist haloperidol. Organometallics 23(19), 4468–4477 (2004).
  CASGoogle Scholar
• 78 Tacke R, Popp F, Müller B et al. Sila-haloperidol, a silicon analog of the dopamine (D₂) receptor antagonist haloperidol: synthesis, pharmacological properties, and metabolic fate. ChemMedChem 3(1), 152–164 (2008). • Sila-haloperidol is an excellent example of Si/C-exchange to change the metabolic fate of the parent carbon analogs.
  Medline CASGoogle Scholar
• 79 Tacke R, Nguyen B, Burschka C et al. Sila-trifluperidol, a silicon analog of the dopamine (D₂) receptor antagonist trifluperidol: synthesis and pharmacological characterization. Organometallics 29(7), 1652–1660 (2010).
  CASGoogle Scholar
• 80 Geyer M, Wellner E, Jurva U, Saloman S, Armstrong D, Tacke R. Can silicon make an excellent drug even better? An in vitro and in vivo head-to-head comparison between loperamide and its silicon analog sila-loperamide. ChemMedChem 10(5), 911–924 (2015).
  Medline CASGoogle Scholar
• 81 Toyama H, Sato S, Shirakawa H, Komai M, Hashimoto Y, Fujii S. Altered activity profile of a tertiary silanol analog of multi-targeting nuclear receptor modulator T0901317. Bioorg. Med. Chem. Lett. 26(7), 1817–1820 (2016).
  Medline CASGoogle Scholar
• 82 Schultz JR, Tu H, Luk A et al. Role of LXRs in control of lipogenesis. Genes Dev. 14(22), 2831–2838 (2000).
  Medline CASGoogle Scholar
• 83 Houck KA, Borchert KM, Hepler CD et al. T0901317 is a dual LXR/FXR agonist. Mol. Genet. Metab. 83(1–2), 184–187 (2004).
  Medline CASGoogle Scholar
• 84 Mitro N, Vargas L, Romeo R, Koder A, Saez E. T0901317 is a potent PXR ligand: implications for the biology ascribed to LXR. FEBS Lett. 581(1), 1721–1726 (2007).
  Medline CASGoogle Scholar
• 85 Kumar N, Solt LA, Conkright JJ et al. The benzenesulfoamide T0901317 [N-(2,2,2-trifluoroethyl)-N-[4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-benzenesulfonamide] is a novel retinoic acid receptor-related orphan receptor-α/γ inverse agonist. Mol. Pharmacol. 77(2), 228–236 (2010).
  Medline CASGoogle Scholar
• 86 Denmark SE, Kallemeyn JM. Palladium-catalyzed silylation of aryl bromides leading to functionalized aryldimethylsilanols. Org. Lett. 5(19), 3483–3486 (2003).
  Medline CASGoogle Scholar
• 87 Blunder M, Hurkes N, Spirk S, List M, Pietschnig R. Silanetriols as in vitro inhibitors for AChE. Bioorg. Med. Chem. Lett. 21(1), 363–365 (2011). • Revealed the potential utility of silanetriols as transition state analogs.
  Medline CASGoogle Scholar
• 88 Puri JK, Singh R, Chahal VK. Silatranes: a review on their synthesis, structure, reactivity and applications. Chem. Soc. Rev. 40(3), 1791–1840 (2011). • For review of silatranes.
  Medline CASGoogle Scholar
• 89 Voronkov MG. Silatranes: intra-complex heterocyclic compounds of pentacordinated silicon. Pure Appl. Chem. 13(1–2), 35–60 (1966).
  CASGoogle Scholar
• 90 Horsham MA, Palmer CJ, Cole LM, Casida JE. 4-Alkynylphenylsilatranes: insecticidal activity, mammalian toxicity, and mode of action. J. Agric. Food Chem. 38(8), 1734–1738 (1990).
  CASGoogle Scholar
• 91 Sculimbrene BR, Decanio RE, Peterson BW, Muntel EE, Fenlon EE. Silatranyl-nucleosides: transition state analogs for phosphoryl transfer reactions. Tetrahedron Lett. 42(30), 4979–4982 (2001).
  CASGoogle Scholar
• 92 Black CA, Ucci JW, Vorpagel JS, Mauck MC, Fenlon EE. Stereoselective and improved syntheses and anticancer testing of 3′-O-silatranylthymidines. Bioorg. Med. Chem. Lett. 12(24), 3521–3523 (2002).
  Medline CASGoogle Scholar
• 93 Rink CM, Mauck MC, Asif I, Pitzer ME, Fenlon EE. Syntheses of silatranyl- and germatranyluridines. Org. Lett. 7(6), 1165–1168 (2005).
  Medline CASGoogle Scholar
• 94 Xiang Y, Fu C, Breiding T et al. Hydrolytically stable octahedral silicon complexes as bioactive scaffolds: application to the design of DNA intercalators. Chem. Commun. 48(57), 7131–7133 (2012).
  Medline CASGoogle Scholar
• 95 Hansch C, Leo A, Unger SH et al. ‘Aromatic’ substituent constants for structure–activity correlations. J. Med. Chem. 16(11), 1207–1216 (1973).
  Medline CASGoogle Scholar